Guido Lanza, Numerate

Guido Lanza is the CEO of Numerate, which he co-founded in 2007 along with a team of computer scientists and drug hunters. Their vision was to change the discovery paradigm through AI – to unlock inaccessible emerging biology and to build a platform capable of learning from all previous data (and mistakes) in the industry. He has led Numerate’s efforts to secure multiple rounds of funding as the company grew and evolved its business model from being primarily a medicinal chemistry service provider for Pharma to an AI-driven company with both major Pharma alliances and a pipeline of first-in-class therapeutic programs. Prior to Numerate, Guido co-founded and was the CTO of another algorithm-focused biotech startup (Pharmix), where he led the development and application of the drug discovery platform. Guido’s background is in Molecular Biology (UC Berkeley) and Bioinformatics (U. of Manchester).

Sessions

Opportunities and Challenges Using AI in unlocking the ADME Tox Obstacles in Drug Development

This session will address how machine and active learning are being applied to solve complex and difficult ADME Tox problems facing the pharma industry. There will be representation from both in-house and external models as well as pro and con viewpoints on applying AI to the challenges of the ADME/tox field. Industry innovators and researchers share their efforts in solving these challenges which could be worth hundreds of millions to industry, accelerate drug discovery and be invaluable to patients.

What problems are we trying to solve?

Do we have the right data to build ADME/Tox models?

How do we know when models will be applicable in a drug discovery program?